MDGL logo

MDGL
Madrigal Pharmaceuticals Inc

6,782
Mkt Cap
$11.11B
Volume
294,188.00
52W High
$496.98
52W Low
$265.00
PE Ratio
-37.61
MDGL Fundamentals
Price
$491.31
Prev Close
$488.58
Open
$488.03
50D MA
$437.14
Beta
0.80
Avg. Volume
282,629.74
EPS (Annual)
-$21.90
P/B
17.75
Rev/Employee
$341,160.98
Loading...
Loading...
News
all
press releases
Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Sells 16,575 Shares of Stock
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) Director Kenneth Bate sold 16,575 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Wednesday, November 5th...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
FY2025 Earnings Estimate for MDGL Issued By B. Riley
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - B. Riley decreased their FY2025 earnings per share (EPS) estimates for Madrigal Pharmaceuticals in a report released on Tuesday, November...
MarketBeat·13h ago
News Placeholder
What is HC Wainwright's Estimate for MDGL FY2025 Earnings?
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Analysts at HC Wainwright lowered their FY2025 EPS estimates for Madrigal Pharmaceuticals in a report released on Wednesday, November 5th...
MarketBeat·13h ago
News Placeholder
Cantor Fitzgerald Brokers Reduce Earnings Estimates for MDGL
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Madrigal...
MarketBeat·13h ago
News Placeholder
Equities Analysts Offer Predictions for MDGL FY2025 Earnings
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a report released on...
MarketBeat·13h ago
News Placeholder
What is B. Riley's Estimate for MDGL Q4 Earnings?
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Research analysts at B. Riley issued their Q4 2026 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a research...
MarketBeat·1d ago
News Placeholder
Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $527.00 at Citizens Jmp
Citizens Jmp lifted their price target on Madrigal Pharmaceuticals from $485.00 to $527.00 and gave the company a "market outperform" rating in a report on Wednesday...
MarketBeat·3d ago
News Placeholder
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
Zacks·3d ago
News Placeholder
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
Madrigal (MDGL) delivered earnings and revenue surprises of -156.57% and +15.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Analysts Estimate electroCore, Inc. (ECOR) to Report a Decline in Earnings: What to Look Out for
electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·10d ago

Latest MDGL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.